Guillermo Garcia-Manero, MD, highlights the ASCERTAIN trial in his opening thoughts surrounding MDS in this ASH 2022 post-conference perspective.
ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)
Dr Garcia-Manero discusses the effects of TP53 mutation in patients with MDS.
Treatment strategies for patients with lower-risk MDS are examined.
In his closing thoughts, Dr Garcia-Manero provides an overview of the treatment management approach for patients with MDS.
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Efficacy and Equity With Oral PCSK9s: Ann Marie Navar, MD, PhD
3
Mitigate Treatment Burden in Heart Failure: Martha Gulati, MD
4
Integrating Sotatercept Into PAH Care: Vallerie McLaughlin, MD
5
